SUBSCRIBE
SUBSCRIBE
News   Business

XenoPort, Inc. Amends Agreement With GlaxoSmithKline On RLS Drug, Horizant; Milestone Payments Changed; Xenoport Reacquires Rights Outside of the U.S.

November 8, 2010 | 
1 min read

Nov 8 (Reuters) - Biopharmaceutical company XenoPort Inc (XNPT.O) amended an agreement with GlaxoSmithKline (GSK.L) for the development of its drug to treat restless legs syndrome (RLS).

Alliances
GlaxoSmithKline
MORE ON THIS TOPIC
Podcast
A Conversation With Kevin Marks, CEO of Delphia
March 4, 2025
 · 
1 min read
 · 
Annalee Armstrong
Contemporary art collage of hand holding a dart aiming at the target. Business targeting, aiming, focus concept. Modern design. Copy space.
NextGen
Delphia Eyes New Precision Medicine Approach: Activation Lethality
March 4, 2025
 · 
2 min read
 · 
Annalee Armstrong
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
CRISPR, Cytiva Laying Off Employees
March 3, 2025
 · 
139 min read
 · 
BioSpace Editorial Staff
AbbVie's office in South San Francisco, California
Obesity
Obesity Late-Comer AbbVie Inks Up to $2.2B Amylin Deal With Gubra
March 3, 2025
 · 
2 min read
 · 
Tristan Manalac